NASDAQ:VOR 11 November 2025 - 9 December 2025

Vor Biopharma priced 10 million new shares at $10 each for $100 million in expected gross proceeds, with underwriters able to buy up to 1.5 million more. Shares fell from $13.03 pre-market to near $10 by mid-morning Tuesday. The offering follows positive Phase 3 IgA nephropathy data from partner RemeGen. The deal is set to close around Nov. 12, 2025, with J.P. Morgan, Jefferies, Citigroup, and TD Cowen as joint bookrunners.